Home › Companies › Bio-Rad Laboratories, Inc. › 2025-2026
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and Bio-Rad Laboratories, Inc.’s Form 8-K, filed April 24, 2026 (Item 5.07 on EDGAR). Page generated November 20, 2026.
Meeting of April 21, 2026: 10 items on Bio-Rad Laboratories, Inc.’s Form 8-K, filed April 24, 2026: 3 approved · 6 passed (calculated) · 1 not approved.
Notable dissent: 1 shareholder proposal (21.2% support); 2 directors (11.7%, 11.2% against).
Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided
Explore Bio-Rad Laboratories, Inc. in the interactive database Compare manager voting policies
These tallies are Bio-Rad Laboratories, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed April 24, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Melinda Litherland | 17,316,523 | 2,297,029 | 28,202 | -- | 1,351,946 | 88% | Passed (calculated) | — |
| Elect Director: Arnold A. Pinkston | 17,423,468 | 2,192,574 | 25,712 | -- | 1,351,946 | 89% | Passed (calculated) | — |
| Elect Director: Jeffrey L. Edwards | 4,991,119 | 346 | 93 | -- | 31,874 | 99.9% | Passed (calculated) | — |
| Elect Director: Gregory K. Hinckley | 4,991,075 | 390 | 93 | -- | 31,874 | 99.9% | Passed (calculated) | — |
| Elect Director: Allison Schwartz | 4,991,152 | 313 | 93 | -- | 31,874 | 99.9% | Passed (calculated) | — |
| Elect Director: Norman Schwartz | 4,990,995 | 470 | 93 | -- | 31,874 | 99.9% | Passed (calculated) | — |
| 2. Proposal to ratify the selection of KPMG LLP as the Company’s independent auditors for the fiscal year ending December 31, 2026 | 7,037,199 | 38,994 | 46,609 | -- | -- | 99.4% | Approved | a majority of the shares outstanding |
| 3. Non-binding advisory vote to approve executive compensation | 6,682,605 | 268,173 | 4,956 | -- | 167,069 | 96% | Approved | a majority of the shares outstanding |
| 4. Proposal to approve the Amended Bio-Rad Laboratories, Inc. 2017 Incentive Award Plan | 6,847,541 | 105,243 | 2,949 | -- | 167,069 | 98% | Approved | a majority of the shares outstanding |
| 5. Stockholder proposal regarding dual class capital structure | 1,469,297 | 5,459,554 | 6,903 | -- | 187,048 | 21% | Not approved | a majority of the shares outstanding |
Source: Bio-Rad Laboratories, Inc., Form 8-K, filed with the SEC on April 24, 2026 — read the filing on EDGAR.
See voting trends for Industrials companies, 2025-2026: shareholder support by sector and by company size.
456 asset managers disclosed a vote on at least one Bio-Rad Laboratories, Inc. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 3 wordings of this item as funds reported it.
89% Majority: yes · of votes cast
Prior year: 82.5% for (April 22, 2025 meeting) ▲ 6.3 pts
Description as filed by funds: Nominees: Arnold A. Pinkston
Bio-Rad Laboratories, Inc.’s own tally for this item (“Elect Director: Arnold A. Pinkston”): 17,423,468 for, 2,192,574 against, per its Form 8-K filed April 24, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 89% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 117 asset managers below reported 7,705,174 for, 828,809 against, 2,872 abstained, 14 not voted.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| FIRST EAGLE FUNDS | 1,957,181 | 0 | 0 | 0 | For |
| Vanguard | 1,644,196 | 806 | 0 | 0 | For |
| Capital Group | 764,042 | 0 | 0 | 0 | For |
| BlackRock | 748,911 | 0 | 0 | 0 | For |
| ARIEL INVESTMENT TRUST | 388,191 | 0 | 0 | 0 | For |
| Dimensional | 347,667 | 0 | 0 | 0 | For |
| Fidelity | 35,004 | 274,678 | 0 | 0 | Mixed |
| MFS | 288,710 | 0 | 0 | 0 | For |
| Investment Managers Series Trust III | 259,106 | 0 | 0 | 0 | For |
| Parnassus | 0 | 253,239 | 0 | 0 | Against |
| LONGLEAF PARTNERS FUNDS TRUST | 185,868 | 0 | 0 | 0 | For |
| Charles Schwab | 182,780 | 31 | 0 | 0 | For |
| John Hancock | 133,408 | 1,737 | 0 | 0 | For |
| Allspring | 94,470 | 0 | 0 | 0 | For |
| PIMCO | 88,186 | 0 | 0 | 0 | For |
| T. Rowe Price | 0 | 80,749 | 0 | 0 | Against |
| Putnam | 0 | 80,552 | 0 | 0 | Against |
| Transamerica | 65,692 | 0 | 0 | 0 | For |
| TRUST FOR PROFESSIONAL MANAGERS | 64,977 | 0 | 0 | 0 | For |
| Equitable | 26,490 | 20,614 | 0 | 0 | Mixed |
| RBB Fund Trust | 46,762 | 0 | 0 | 0 | For |
| BOSTON TRUST WALDEN FUNDS | 0 | 38,293 | 0 | 0 | Against |
| Jackson National | 36,655 | 0 | 0 | 0 | For |
| FRANKLIN VALUE INVESTORS TRUST | 0 | 34,773 | 0 | 0 | Against |
| TIAA | 26,327 | 0 | 0 | 0 | For |
Showing the 25 largest of 117 asset managers. All 117 are in the interactive database (link above).
Combines 3 wordings of this item as funds reported it.
88% Majority: yes · of votes cast
Prior year: 81.0% for (April 22, 2025 meeting) ▲ 7.3 pts
Description as filed by funds: Nominees: Melinda Litherland
Bio-Rad Laboratories, Inc.’s own tally for this item (“Elect Director: Melinda Litherland”): 17,316,523 for, 2,297,029 against, per its Form 8-K filed April 24, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 88% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 117 asset managers below reported 7,704,826 for, 829,157 against, 2,872 abstained, 14 not voted.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| FIRST EAGLE FUNDS | 1,957,181 | 0 | 0 | 0 | For |
| Vanguard | 1,644,196 | 806 | 0 | 0 | For |
| Capital Group | 764,042 | 0 | 0 | 0 | For |
| BlackRock | 748,911 | 0 | 0 | 0 | For |
| ARIEL INVESTMENT TRUST | 388,191 | 0 | 0 | 0 | For |
| Dimensional | 347,667 | 0 | 0 | 0 | For |
| Fidelity | 35,004 | 274,678 | 0 | 0 | Mixed |
| MFS | 288,710 | 0 | 0 | 0 | For |
| Investment Managers Series Trust III | 259,106 | 0 | 0 | 0 | For |
| Parnassus | 0 | 253,239 | 0 | 0 | Against |
| LONGLEAF PARTNERS FUNDS TRUST | 185,868 | 0 | 0 | 0 | For |
| Charles Schwab | 182,780 | 31 | 0 | 0 | For |
| John Hancock | 133,408 | 1,737 | 0 | 0 | For |
| Allspring | 94,470 | 0 | 0 | 0 | For |
| PIMCO | 88,186 | 0 | 0 | 0 | For |
| T. Rowe Price | 0 | 80,749 | 0 | 0 | Against |
| Putnam | 0 | 80,552 | 0 | 0 | Against |
| Transamerica | 65,692 | 0 | 0 | 0 | For |
| TRUST FOR PROFESSIONAL MANAGERS | 64,977 | 0 | 0 | 0 | For |
| Equitable | 26,490 | 20,614 | 0 | 0 | Mixed |
| RBB Fund Trust | 46,762 | 0 | 0 | 0 | For |
| BOSTON TRUST WALDEN FUNDS | 0 | 38,293 | 0 | 0 | Against |
| Jackson National | 36,655 | 0 | 0 | 0 | For |
| FRANKLIN VALUE INVESTORS TRUST | 0 | 34,773 | 0 | 0 | Against |
| TIAA | 26,327 | 0 | 0 | 0 | For |
Showing the 25 largest of 117 asset managers. All 117 are in the interactive database (link above).
Combines 3 wordings of this item as funds reported it.
98% Approved · of votes cast
Description as filed by funds: Approval of the Amended Bio-Rad Laboratories, Inc. 2017 Incentive Award Plan.
Bio-Rad Laboratories, Inc.’s own tally for this item (“4. The proposal to approve the Amended Bio-Rad Laboratories, Inc. 2017 Incentive Award Plan”): 6,847,541 for, 105,243 against — passed, per its Form 8-K filed April 24, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The proposal to approve the Amended Bio-Rad Laboratories, Inc. 2017 Incentive Award Plan was approved and received the affirmative vote of a majority of the voting power of the holders of Class A and Class B Common Stock, as follows: Votes | Votes | Votes | Broker For | Against | Abstaining | Non-V…”
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Voting standard, as the filing states it: a majority of the shares outstanding (“majority of the voting power”).
Also reported under other wordings, matched to the same row of Bio-Rad Laboratories, Inc.’s official tally and shown with their own fund figures; their managers are not in the figures or the table on this card: “Amend Omnibus Stock Plan” (4 managers, 16,362 for).
Fund share totals are not shown for this item: fund-reported shares overlap across filings (an adviser and the funds it manages can each report the same shares), and here their sum exceeds the total votes cast at the meeting.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| FIRST EAGLE FUNDS | 1,957,181 | 0 | 0 | 0 | For |
| Vanguard | 1,645,001 | 1 | 0 | 0 | For |
| Capital Group | 764,042 | 0 | 0 | 0 | For |
| BlackRock | 748,911 | 0 | 0 | 0 | For |
| ARIEL INVESTMENT TRUST | 388,191 | 0 | 0 | 0 | For |
| Dimensional | 347,667 | 0 | 0 | 0 | For |
| Fidelity | 309,682 | 0 | 0 | 0 | For |
| MFS | 288,710 | 0 | 0 | 0 | For |
| Investment Managers Series Trust III | 259,106 | 0 | 0 | 0 | For |
| Parnassus | 253,239 | 0 | 0 | 0 | For |
| LONGLEAF PARTNERS FUNDS TRUST | 185,868 | 0 | 0 | 0 | For |
| Charles Schwab | 182,811 | 0 | 0 | 0 | For |
| John Hancock | 135,145 | 0 | 0 | 0 | For |
| Allspring | 94,470 | 0 | 0 | 0 | For |
| PIMCO | 88,186 | 0 | 0 | 0 | For |
| T. Rowe Price | 80,749 | 0 | 0 | 0 | For |
| Putnam | 80,552 | 0 | 0 | 0 | For |
| Transamerica | 65,692 | 0 | 0 | 0 | For |
| TRUST FOR PROFESSIONAL MANAGERS | 64,977 | 0 | 0 | 0 | For |
| Equitable | 47,104 | 0 | 0 | 0 | For |
| RBB Fund Trust | 46,762 | 0 | 0 | 0 | For |
| BOSTON TRUST WALDEN FUNDS | 38,293 | 0 | 0 | 0 | For |
| Jackson National | 36,655 | 0 | 0 | 0 | For |
| FRANKLIN VALUE INVESTORS TRUST | 34,773 | 0 | 0 | 0 | For |
| TIAA | 26,327 | 0 | 0 | 0 | For |
Showing the 25 largest of 120 asset managers. All 120 are in the interactive database (link above).
Combines 8 wordings of this item as funds reported it.
96% Approved · of votes cast
Description as filed by funds: Advisory vote to approve executive compensation.
Bio-Rad Laboratories, Inc.’s own tally for this item (“3. The non-binding advisory vote to approve executive compensation”): 6,682,605 for, 268,173 against — passed, per its Form 8-K filed April 24, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The non-binding advisory vote to approve executive compensation was approved and received the affirmative vote of a majority of the voting power of the holders of Class A and Class B Common Stock, as follows: Votes | Votes | Votes | Broker For | Against | Abstaining | Non-Votes 6,682,605 | 268,173 …”
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Voting standard, as the filing states it: a majority of the shares outstanding (“majority of the voting power”).
Also reported under other wordings, matched to the same row of Bio-Rad Laboratories, Inc.’s official tally and shown with their own fund figures; their managers are not in the figures or the table on this card: “Advisory Vote to Ratify Named Executive Officers' Compensation” (10 managers, Fund and manager reports combined; may count the same shares twice; no share total shown).
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| FIRST EAGLE FUNDS | 1,957,181 | 0 | 0 | 0 | For |
| Vanguard | 1,645,000 | 1 | 0 | 0 | For |
| Capital Group | 0 | 764,042 | 0 | 0 | Against |
| BlackRock | 748,911 | 0 | 0 | 0 | For |
| ARIEL INVESTMENT TRUST | 388,191 | 0 | 0 | 0 | For |
| Dimensional | 347,667 | 0 | 0 | 0 | For |
| Fidelity | 309,493 | 189 | 0 | 0 | For |
| MFS | 288,710 | 0 | 0 | 0 | For |
| Investment Managers Series Trust III | 259,106 | 0 | 0 | 0 | For |
| Parnassus | 253,239 | 0 | 0 | 0 | For |
| LONGLEAF PARTNERS FUNDS TRUST | 185,868 | 0 | 0 | 0 | For |
| Charles Schwab | 182,811 | 0 | 0 | 0 | For |
| John Hancock | 135,145 | 0 | 0 | 0 | For |
| Allspring | 94,470 | 0 | 0 | 0 | For |
| PIMCO | 88,186 | 0 | 0 | 0 | For |
| T. Rowe Price | 80,749 | 0 | 0 | 0 | For |
| Putnam | 80,552 | 0 | 0 | 0 | For |
| Transamerica | 65,692 | 0 | 0 | 0 | For |
| TRUST FOR PROFESSIONAL MANAGERS | 64,977 | 0 | 0 | 0 | For |
| Equitable | 47,104 | 0 | 0 | 0 | For |
| RBB Fund Trust | 46,762 | 0 | 0 | 0 | For |
| BOSTON TRUST WALDEN FUNDS | 0 | 38,293 | 0 | 0 | Against |
| Jackson National | 6,010 | 30,645 | 0 | 0 | Mixed |
| FRANKLIN VALUE INVESTORS TRUST | 34,773 | 0 | 0 | 0 | For |
| TIAA | 26,327 | 0 | 0 | 0 | For |
No total is shown for the fund voting reports: their sum exceeds the total votes cast at the meeting. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| First Eagle Investment Management, LLC | 2,360,553 | 0 | 0 | 0 | For |
| BlackRock | 516,896 | 951 | 0 | 0 | For |
| EARNEST PARTNERS LLC | 163,973 | 329,131 | 0 | 0 | Mixed |
| MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | 456,503 | 0 | 0 | 0 | For |
| Capital Group | 1 | 450,000 | 0 | 0 | Against |
| First Pacific Advisors, LP | 400,789 | 0 | 0 | 0 | For |
| State Street | 392,839 | 4,805 | 0 | 0 | For |
| UBS | 0 | 342,918 | 0 | 0 | Against |
| GEODE CAPITAL MANAGEMENT, LLC | 340,465 | 0 | 0 | 0 | For |
| Capital Research Global Investors | 0 | 314,042 | 0 | 0 | Against |
| Parnassus | 253,239 | 0 | 0 | 0 | For |
| ARIEL INVESTMENTS, LLC | 244,343 | 0 | 0 | 0 | For |
| Mawer Investment Management Ltd. | 0 | 201,944 | 0 | 0 | Against |
| Charles Schwab | 183,773 | 0 | 0 | 0 | For |
| Northern Trust | 174,203 | 632 | 0 | 0 | For |
| DEERFIELD MANAGEMENT COMPANY, L.P. | 170,602 | 0 | 0 | 0 | For |
| GW&K Investment Management, LLC | 169,537 | 0 | 0 | 0 | For |
| THOMPSON SIEGEL & WALMSLEY LLC | 167,602 | 0 | 0 | 0 | For |
| Vanguard | 142,196 | 0 | 0 | 0 | For |
| John Hancock | 127,662 | 0 | 0 | 0 | For |
| T. Rowe Price | 127,614 | 0 | 0 | 0 | For |
| ACADIAN ASSET MANAGEMENT LLC | 125,969 | 0 | 0 | 0 | For |
| MELLON INVESTMENTS Corp | 56 | 123,732 | 0 | 0 | Against |
| Putnam | 115,202 | 0 | 0 | 0 | For |
| Allspring | 109,304 | 0 | 0 | 0 | For |
No total is shown for the institutional-manager reports: their sum exceeds the total votes cast at the meeting. Showing the 25 largest; every one is in the interactive database (link above).
Combines 4 wordings of this item as funds reported it.
99.4% Approved · of votes cast
Prior year: 99.3% for (April 22, 2025 meeting) ▲ 0.2 pts
Description as filed by funds: Proposal to ratify the selection of KPMG LLP to serve as the Company's independent auditors.
Bio-Rad Laboratories, Inc.’s own tally for this item (“2. The proposal to ratify the selection of KPMG LLP as the Company’s independent auditors for the fiscal year ending December 31, 2026”): 7,037,199 for, 38,994 against — passed, per its Form 8-K filed April 24, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The proposal to ratify the selection of KPMG LLP as the Company’s independent auditors for the fiscal year ending December 31, 2026 was ratified and received the affirmative vote of a majority of the voting power of the holders of Class A and Class B Common Stock, as follows: Votes | Votes | Votes …”
Support: 99.4% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Voting standard, as the filing states it: a majority of the shares outstanding (“majority of the voting power”).
Fund share totals are not shown for this item: fund-reported shares overlap across filings (an adviser and the funds it manages can each report the same shares), and here their sum exceeds the total votes cast at the meeting.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| FIRST EAGLE FUNDS | 1,957,181 | 0 | 0 | 0 | For |
| Vanguard | 1,645,001 | 0 | 0 | 0 | For |
| Capital Group | 764,042 | 0 | 0 | 0 | For |
| BlackRock | 748,911 | 0 | 0 | 0 | For |
| ARIEL INVESTMENT TRUST | 388,191 | 0 | 0 | 0 | For |
| Dimensional | 347,667 | 0 | 0 | 0 | For |
| Fidelity | 309,682 | 0 | 0 | 0 | For |
| MFS | 288,710 | 0 | 0 | 0 | For |
| Investment Managers Series Trust III | 259,106 | 0 | 0 | 0 | For |
| Parnassus | 253,239 | 0 | 0 | 0 | For |
| LONGLEAF PARTNERS FUNDS TRUST | 185,868 | 0 | 0 | 0 | For |
| Charles Schwab | 182,811 | 0 | 0 | 0 | For |
| John Hancock | 135,145 | 0 | 0 | 0 | For |
| Allspring | 94,470 | 0 | 0 | 0 | For |
| PIMCO | 88,186 | 0 | 0 | 0 | For |
| T. Rowe Price | 80,749 | 0 | 0 | 0 | For |
| Putnam | 80,552 | 0 | 0 | 0 | For |
| Transamerica | 65,692 | 0 | 0 | 0 | For |
| TRUST FOR PROFESSIONAL MANAGERS | 64,977 | 0 | 0 | 0 | For |
| Equitable | 47,104 | 0 | 0 | 0 | For |
| RBB Fund Trust | 46,762 | 0 | 0 | 0 | For |
| BOSTON TRUST WALDEN FUNDS | 38,293 | 0 | 0 | 0 | For |
| Jackson National | 36,655 | 0 | 0 | 0 | For |
| FRANKLIN VALUE INVESTORS TRUST | 34,773 | 0 | 0 | 0 | For |
| TIAA | 26,327 | 0 | 0 | 0 | For |
Showing the 25 largest of 118 asset managers. All 118 are in the interactive database (link above).
Proposed by: John Chevedden
Combines 4 wordings of this item as funds reported it.
21% Not approved · of votes cast
Description as filed by funds: Stockholder proposal regarding dual class capital structure.
Bio-Rad Laboratories, Inc.’s own tally for this item (“5. The stockholder proposal regarding dual class capital structure”): 1,469,297 for, 5,459,554 against — failed, per its Form 8-K filed April 24, 2026 (Item 5.07).
Reported outcome: Not approved, in the filing’s own words: “The stockholder proposal regarding dual class capital structure was not approved since the proposal did not receive the affirmative vote of a majority of the voting power of the holders of Class A and Class B Common Stock”
Support: 21% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Voting standard, as the filing states it: a majority of the shares outstanding (“majority of the voting power”).
Fund share totals are not shown for this item: fund-reported shares overlap across filings (an adviser and the funds it manages can each report the same shares), and here their sum exceeds the total votes cast at the meeting.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| FIRST EAGLE FUNDS | 1,957,181 | 0 | 0 | 0 | For |
| Vanguard | 1,627,416 | 17,586 | 0 | 0 | For |
| Capital Group | 764,042 | 0 | 0 | 0 | For |
| BlackRock | 748,911 | 0 | 0 | 0 | For |
| ARIEL INVESTMENT TRUST | 0 | 388,191 | 0 | 0 | Against |
| Dimensional | 347,667 | 0 | 0 | 0 | For |
| Fidelity | 309,682 | 0 | 0 | 0 | For |
| MFS | 288,710 | 0 | 0 | 0 | For |
| Investment Managers Series Trust III | 0 | 259,106 | 0 | 0 | Against |
| Parnassus | 253,239 | 0 | 0 | 0 | For |
| LONGLEAF PARTNERS FUNDS TRUST | 185,868 | 0 | 0 | 0 | For |
| Charles Schwab | 182,722 | 89 | 0 | 0 | For |
| John Hancock | 135,145 | 0 | 0 | 0 | For |
| Allspring | 94,470 | 0 | 0 | 0 | For |
| PIMCO | 88,186 | 0 | 0 | 0 | For |
| T. Rowe Price | 80,749 | 0 | 0 | 0 | For |
| Putnam | 80,552 | 0 | 0 | 0 | For |
| Transamerica | 65,692 | 0 | 0 | 0 | For |
| TRUST FOR PROFESSIONAL MANAGERS | 64,977 | 0 | 0 | 0 | For |
| Equitable | 27,104 | 20,000 | 0 | 0 | Mixed |
| RBB Fund Trust | 46,762 | 0 | 0 | 0 | For |
| BOSTON TRUST WALDEN FUNDS | 38,293 | 0 | 0 | 0 | For |
| Jackson National | 34,200 | 2,455 | 0 | 0 | Mixed |
| FRANKLIN VALUE INVESTORS TRUST | 34,773 | 0 | 0 | 0 | For |
| TIAA | 26,327 | 0 | 0 | 0 | For |
Showing the 25 largest of 116 asset managers. All 116 are in the interactive database (link above).
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 26,958,000 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | FIRST EAGLE FUNDS | 7.26% |
| 2 | Vanguard | 6.10% |
| 3 | Capital Group | 2.83% |
| 4 | BlackRock | 2.78% |
| 5 | ARIEL INVESTMENT TRUST | 1.44% |
| 6 | Dimensional | 1.29% |
| 7 | Fidelity | 1.15% |
| 8 | MFS | 1.07% |
| 9 | Investment Managers Series Trust III | 0.96% |
| 10 | Parnassus | 0.94% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | First Eagle Investment Management, LLC | 8.76% |
| 2 | BlackRock | 1.92% |
| 3 | EARNEST PARTNERS LLC | 1.83% |
| 4 | MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | 1.69% |
| 5 | Capital Group | 1.67% |
| 6 | First Pacific Advisors, LP | 1.49% |
| 7 | State Street | 1.48% |
| 8 | UBS | 1.27% |
| 9 | GEODE CAPITAL MANAGEMENT, LLC | 1.26% |
| 10 | Capital Research Global Investors | 1.16% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.
| Holder | Shares | % outstanding | Source, as of |
|---|---|---|---|
| Vanguard Group | 1,774,263 | 6.58% | Form 13F, quarter ended March 31, 2026 |
| BlackRock | 1,680,060 | 6.23% | Form 13F, quarter ended March 31, 2026 |
| Dimensional Fund Advisors | 1,089,323 | 4.04% | Form 13F, quarter ended March 31, 2026 |
| State Street | 559,570 | 2.08% | Form 13F, quarter ended March 31, 2026 |
| Geode Capital | 364,682 | 1.35% | Form 13F, quarter ended March 31, 2026 |
| Northern Trust | 218,497 | 0.81% | Form 13F, quarter ended March 31, 2026 |
| Charles Schwab | 196,558 | 0.73% | Form 13F, quarter ended March 31, 2026 |
| Morgan Stanley | 186,387 | 0.69% | Form 13F, quarter ended March 31, 2026 |
| Franklin Templeton | 170,354 | 0.63% | Form 13F, quarter ended March 31, 2026 |
| Citadel Advisors | 150,269 | 0.56% | Form 13F, quarter ended March 31, 2026 |
Percentages above are of 26,958,000 shares outstanding, as reported by Bio-Rad Laboratories, Inc. on its Form 10-Q dated March 31, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
At Bio-Rad Laboratories, Inc.'s shareholder meeting held April 21, 2026, in the 2025-2026 proxy season, 456 asset managers reported votes on at least one of its 6 ballot items in their SEC Form N-PX filings, covering 2,975 separate fund positions. On the most widely held item on that ballot — Advisory vote to approve executive compensation. — Bio-Rad Laboratories, Inc.'s filing reports the proposal as approved, with 96% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: Bio-Rad Laboratories, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on April 24, 2026.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Bio-Rad Laboratories, Inc.’s 10-Q dated March 31, 2026. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.
Bio-Rad Laboratories, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).
Proxy Votes Now, “Bio-Rad Laboratories (BIO) 2026 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/bio-rad-laboratories-inc/2026 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.